Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy.

• DOI: 10.1200/jco.2011.29.15_suppl.7607
• Publication Date: 2017-02-23T13:58:03Z
• Authors: S. Heon; B. Y. Yeap; N. I. Lindeman; M. S. Rabin; D. M. Jackman; B. E. Johnson
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

7607 Background: The impact of tumor genotype and targeted therapies on the control development CNS metastases from NSCLC has not been extensively studied. We recently reported a lower than expected rate progression in patients with advanced somatic EGFR mutations initially treated gefitinib or erlotinib. This retrospective study was undertaken to investigate erlotinib versus chemotherapy risk mutant patients. Methods: Patients stage IV relapsed seen at DFCI between 8/00 2/10 who were without receiving for least 6 months identified prospective trial. cumulative calculated using death as competing risk. Results: 129 eligible (99 EGFR-TKI, 30 chemotherapy). 21 (21%) EGFR-TKI group 9 (30%) had brain time diagnosis (P=0.331); 28 received therapy before initiating systemic treatment. 15 (50%) developed after median potential follow-up 49 (P=0.04). 1- 2-year 5% (95% CI, 2–11) 21% 13–30), respectively, compared corresponding rates 24% 10–40) 31% 15–48) group. PFS prolonged an (median 11.5 vs. 6.9 mo; P<0.001), whereas there no difference OS 32.2 36.2 P=0.366). Conclusions: Our data suggest upfront chemotherapy. Additional are undergoing sequencing increase number